Five things for pharma marketers to know: Tuesday, January 26, 2016
1. Boehringer Ingelheim said the FDA accepted a supplemental new drug application for Jardiance that shows the drug reduces the risk of cardiovascular death in diabetes patients. The regulator approved Jardiance in 2014 and the drugmaker launched a DTC campaign for the drug this past fall.
2. Sen. Edward Markey (D-Mass.) blocked the nomination of Dr. Robert Califf as FDA commissioner over concerns about the agency's approval of a opioid painkiller for children. The move puts a hold on Califf's nomination. (Boston Globe)
3. GlaxoSmithKline plans to wrap up feasibility studies that are looking at whether its vaccine technology can be used for the Zika virus. Vaccine development takes between 10 and 15 years. (Reuters)
4. Facing criticism from the research community, the editor-in-chief of the New England Journal of Medicine said the medical journal is committed to data sharing for clinical trials. The editor, Jeffrey Drazen, last week published an editorial expressing concerns about data sharing. (MedPage Today)
5. Galapagos, a Belgian biotechnology firm, said its experimental drug to treat ulcerative colitis did not perform better than placebo. The drugmaker plans to test the drug for other indications. (Reuters)